Brief: Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases
23/04/2025 12:05
April 23 (Reuters) - Rein Therapeutics Inc RNTX.O: REIN THERAPEUTICS GRANTED TWO PATENTS COVERING THE NOVEL FORMULATION AND ADMINISTRATION METHODS OF DRY POWDER LTI-03 FOR THE TREATMENT OF RESPIRATORY DISEASES Source text: ID:nPn7x5myja Further company coverage: RNTX.O ((reuters.briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering